A national proficiency scheme for human leucocyte antigen typing by next-generation sequencing

Lin, Guigao; Zhang, Kuo; Li, Jinming

doi:10.1016/j.cca.2022.06.015

Cited by 4 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… Lin et al (2022) described the EPT results with a national proficiency scheme from China performing HLA typing by NGS by 24 laboratories in 2021. Comparing their results with ours revealed an overall concordance rate for all HLA alleles typed of 99.2% in the China EPT and 99.5% in ours for both 2021 and 2022.…”

Section: Discussionmentioning

confidence: 99%

“…Therefore, we always provided an overview of all results with the errors highlighted and an explanation of the errors in detail in the accompanying letter with the intention to raise specific awareness about the presence of null alleles, the presence of genotype ambiguities, and the correct reporting of allele ambiguities. Lin et al (2022) described the EPT results with a national proficiency scheme from China performing HLA typing by NGS by 24 laboratories in 2021. Comparing their results with ours revealed an overall concordance rate for all HLA alleles typed of 99.2% in the China EPT and 99.5% in ours for both 2021 and 2022.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of 19 years of international external proficiency testing for high-resolution HLA typing

Voorter,

Groeneveld,

Heidt

et al. 2024

Front. Genet.

View full text Add to dashboard Cite

The international high-resolution external proficiency testing (EPT) started in 2004 with high-resolution typing of human leucocyte antigen (HLA) class I (HLA-A,B,C) and HLA class II (HLA-DRB1, DRB345, DQB1, and DPB1) alleles, since possibilities for such an EPT within Europe were limited and all existing EPTs at that time made use of the comparison of HLA typing results without a reference. This EPT was set up as a collaboration between the HLA laboratory of Leiden, providing DNA samples to the participants, and the laboratory of Maastricht, performing the high-resolution typing as the reference result and evaluating the results of all participants according to the prevailing European Federation for Immunogenetics (EFI) standards. Once a year, 12 samples were sent to the participating laboratories, and evaluation and certificates were provided at the end of that same year. During the years, the EPT was extended to low-resolution HLA class I and II typing, high-resolution typing including DQA1 and DPA1, and allelic resolution typing for HLA class I, the latter one being unique in this field. Evaluation of the high-resolution typing results of the last 19 years showed a clear increase in the number of loci tested by the participating laboratories and a clear change of method from Sanger sequencing with additional other techniques (SSO/SSP) to the nowadays widely used next-generation sequencing method. By strictly using the EFI rules for high-resolution HLA typing, the participants were made aware of the ambiguities within exons 2 and 3 for class I and exon 2 for class II and the presence of null alleles even in a two-field HLA typing. There was an impressive learning curve, resulting in >98% correctly typed samples since 2017 and a 100% fulfillment of EFI rules for all laboratories for all loci submitted in the last 2 years. Overall, this EPT meets the need of an EPT for high-resolution typing for EFI accreditation.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Evaluation of 19 years of international external proficiency testing for high-resolution HLA typing

Voorter,

Groeneveld,

Heidt

et al. 2024

Front. Genet.

View full text Add to dashboard Cite

show abstract

The European Organisation of External Quality Assurance Providers in Laboratory Medicine (EQALM) Statement: guidelines for publishing about interlaboratory comparison studies (PubILC)

Buchta,

Gidske,

Henriksen

et al. 2024

Critical Reviews in Clinical Laboratory Sciences

View full text Add to dashboard Cite

Update on HLA-B15:02* Allele Associated with Adverse Drug Reactions

Zhu,

Luo,

Zheng

2024

Pharmacogenomics

View full text Add to dashboard Cite

HLA alleles, part of the major histocompatibility complex, are strongly associated with adverse drug reactions (ADRs). This review focuses on HLA-B*15:02 and explores its association with ADRs in various ethnic populations and with different drugs, aiming to provide insights into the safe clinical use of drugs and minimize the occurrence of ADRs. Furthermore, the review explores the potential mechanisms by which HLA-B*15:02 may be associated with ADRs, aiming to gain new insights into drug modification and identification of haptens. In addition, it analyzes the frequency of the HLA-B*15:02, genotyping methods, cost–effectiveness and treatment measures for adverse reactions, thereby providing a theoretical basis for formulating clinical treatment plans.

show abstract

A national proficiency scheme for human leucocyte antigen typing by next-generation sequencing

Cited by 4 publications

References 15 publications

Evaluation of 19 years of international external proficiency testing for high-resolution HLA typing

Evaluation of 19 years of international external proficiency testing for high-resolution HLA typing

The European Organisation of External Quality Assurance Providers in Laboratory Medicine (EQALM) Statement: guidelines for publishing about interlaboratory comparison studies (PubILC)

Update on HLA-B15:02* Allele Associated with Adverse Drug Reactions

Contact Info

Product

Resources

About

A national proficiency scheme for human leucocyte antigen typing by next-generation sequencing

Cited by 4 publications

References 15 publications

Evaluation of 19 years of international external proficiency testing for high-resolution HLA typing

Evaluation of 19 years of international external proficiency testing for high-resolution HLA typing

The European Organisation of External Quality Assurance Providers in Laboratory Medicine (EQALM) Statement: guidelines for publishing about interlaboratory comparison studies (PubILC)

Update on HLA-B*15:02 Allele Associated with Adverse Drug Reactions

Contact Info

Product

Resources

About

Update on HLA-B15:02* Allele Associated with Adverse Drug Reactions